Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD

Dew, Rachel E; Kollins, Scott H

doi:10.1517/14656566.2010.531009

Cited by 14Attention Deficit Hyperactivity DisorderPharmacology and Obesity TreatmentPharmaceutical studies and practices

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD

Dew, Rachel E, Kollins, Scott H·2010·Expert Opinion on Pharmacotherapy

DOI 10.1517/14656566.2010.531009

Open this paper in CoChat — free account

Abstract

Importance of the field Attention deficit/hyperactivity disorder (ADHD), a prevalent disorder in children and adults, presents a substantial societal burden in both monetary cost and human suffering. Characterized by significant difficulties in maintaining attention, completing tasks, motor control, and appropriate social engagement, the disorder begins early in life and results in significant impairment across domains of functioning, including social, educational, and occupational achievement. The condition also carries heightened risk of substance use and dependence, and criminal activity. Pharmacologic treatment is a key component of ADHD management and has been found to be cost effective and generally well tolerated. However, despite increasing options for medication therapy, community management of ADHD is suboptimal. This review assesses current research on lisdexamfetamine dimesylate (LDX), a relatively recent addition to the range of treatment options. Areas covered in this review This review summarizes peer-reviewed literature on LDX published 2003 - 2010. What the reader will gain The reader will gain insight into the efficacy and safety of LDX in the treatment of ADHD, and its place in the clinical armamentarium. Take home message LDX is a useful addition to the formulary, showing similar efficacy and safety profiles to other stimulants.

Integrity signals

Registry

Crossref · 10.1517/14656566.2010.531009

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

LDX modulates seven human protein targets: it activates TAAR1 and inhibits SLC18A2, DAT, NET, SERT, MAOA, and MAOB.
“LDX has been reported to modulate with pharmacological action of seven human protein targets (Table 2). On the one hand, it acts as activator of TAAR1. On the other hand, six protein targets are inhibited by LDX: synaptic vesicular amine transporter (SLC18A2), DAT (SLC6A3), NET (SLC6A2), SERT (SLC6A4) and amine oxidase [flavin-containing] (MAO) A and B [153–157].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [154]
All of these targets are involved in presynaptic signalling, and LDX therefore has a role in regulating three main NT pathways: DA, NE and serotonin.
“All of these targets are involved in the presynaptic signalling, and LDX therefore has a role in regulating three main NT pathways: DA, NE and serotonin.”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [154]

The Prevalence and Correlates of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · see citing works
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765 · see citing works
Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children.
Froehlich, T. E., Lanphear, B., Epstein, J. N., Barbaresi, W., Katusic, S., & Kahn, R. (2007) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.161.9.857 · Cited by 779 · see citing works
Illicit Use of Specific Prescription Stimulants Among College Students: Prevalence, Motives, and Routes of Administration
Teter, C. J., McCabe, S. E., LaGrange, K., Cranford, J. A., & Boyd, C. J. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.10.1501 · Cited by 540 · see citing works
Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study
Biederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80083-x · Cited by 404 · see citing works
Once-a-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings
Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M., Chronis, A. M., Forehand, G. L., Nguyen, C. A., Hoffman, M. T., et al. (2001) · Pediatrics · doi:10.1542/peds.107.6.e105 · Cited by 378 · see citing works
Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study
Biederman, J., Boellner, S. W., Childress, A., Lopez, F. A., Krishnan, S., & Zhang, Y. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.015 · Cited by 356 · see citing works
Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Vetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., & Webb, C. L. (2008) · Circulation · doi:10.1161/circulationaha.107.189473 · Cited by 296 · see citing works
Review of Medication Adherence in Children and Adults with ADHD
Adler, L. D., & Nierenberg, A. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2112 · Cited by 295 · see citing works
Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0903 · Cited by 218 · see citing works
Self-citation
The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
Heal, D. J., Cheetham, S. C., & Smith, S. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.020 · Cited by 198 · see citing works
Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder: Epidemiology, Prevention and Management
Graham, J., & Coghill, D. (2008) · CNS Drugs · doi:10.2165/00023210-200822030-00003 · Cited by 185 · see citing works
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103113 · Cited by 149 · see citing works
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design
Wigal, T., Brams, M., Gasior, M., Gao, J., Squires, L., Giblin, J., & 316 Study Group (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-34 · Cited by 136 · cited 2× · see citing works
“Pivotal trial(s) [22,30,33,36] Lisdexamfetamine dimesylate”
Method
ADHD, Substance Use Disorders, and Psychostimulant Treatment: Current Literature and Treatment Guidelines
Kollins, S. H. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707311654 · Cited by 136 · see citing works
Self-citation
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review
Findling, R. L. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.006 · Cited by 129 · see citing works
Medication Adherence in the MTA: Saliva Methylphenidate Samples Versus Parent Report and Mediating Effect of Concomitant Behavioral Treatment
Pappadopulos, E., Jensen, P. S., Chait, A. R., Arnold, L. E., Swanson, J. M., Greenhill, L. L., Hechtman, L., Chuang, S., Wells, K. C., Pelham, W., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31819c23ed · Cited by 112 · cited 1× · see citing works
“The complex medical dosing schedules that were prevalent before the more recent long-acting formulations became available have also been associated with poor compliance [4,7,13].”
Background
A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder
the 311 Study Group, Wigal, S. B., Kollins, S. H., Childress, A. C., & Squires, L. (2009) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-3-17 · Cited by 112 · see citing works
Self-citation
Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers
Jasinski, D., & Krishnan, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093841 · Cited by 100 · see citing works
Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Weisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900024056 · Cited by 94 · see citing works
Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder
Findling, R. L., Childress, A. C., Krishnan, S., & McGough, J. J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016898 · Cited by 90 · see citing works
Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate
Krishnan, S. M., Pennick, M., & Stark, J. G. (2008) · Clinical Drug Investigation · doi:10.2165/0044011-200828120-00002 · Cited by 85 · see citing works
A clinical review of outcomes of the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA)
Murray, D. W., Arnold, L. E., Swanson, J., Wells, K., Burns, K. E. A., Jensen, P. S., Hechtman, L. T., Paykina, N., Legato, L. J., & Strauss, T. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0068-4 · Cited by 80 · see citing works
Relative Bioavailability of Lisdexamfetamine 70‐mg Capsules in Fasted and Fed Healthy Adult Volunteers and in Solution: A Single‐Dose, Crossover Pharmacokinetic Study
Krishnan, S., & Zhang, Y. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007310381 · Cited by 73 · see citing works
Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers
Ermer, J., Homolka, R., Martin, P., Buckwalter, M., Purkayastha, J., & Roesch, B. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009357346 · Cited by 72 · see citing works
Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study
Boellner, S. W., Stark, J. G., Krishnan, S., & Zhang, Y. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.02.011 · Cited by 72 · see citing works
Adverse Reactions to Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder: Structure and Associations with Clinical Characteristics and Symptom Control
Sonuga-Barke, E. J. S., Coghill, D., Wigal, T., DeBacker, M., & Swanson, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0024 · Cited by 71 · see citing works
New Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder
Connor, D. F., & Steingard, R. J. (2004) · CNS Drugs · doi:10.2165/00023210-200418140-00005 · Cited by 71 · see citing works
An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes
Krishnan, S., & Moncrief, S. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011973 · Cited by 50 · see citing works
Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder
Olfson, M., Marcus, S. C., Zhang, H. F., & Wan, G. J. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.7.570 · Cited by 48 · see citing works
Short-Term Effects of Lisdexamfetamine Dimesylate on Cardiovascular Parameters in a 4-Week Clinical Trial in Adults With Attention-Deficit/Hyperactivity Disorder
Adler, L. A., Weisler, R. H., Goodman, D. W., Hamdani, M., & Niebler, G. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05335pur · Cited by 42 · cited 1× · see citing works
“active treatment group; they therefore recommend that cardiovascular monitoring should be part of standard care with LDX [34].”
Background
Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth
Faraone, S. V., Spencer, T. J., Kollins, S. H., & Glatt, S. J. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-201001000-00006 · Cited by 39 · see citing works
Self-citation
Three-Year Follow-Up of Syndromal Antisocial Behavior in Adults
Goldstein, R. B., & Grant, B. F. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04545 · Cited by 29 · see citing works
Assessing methylphenidate preference in ADHD patients using a choice procedure
Fredericks, E. M., & Kollins, S. H. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1838-2 · Cited by 28 · see citing works
Self-citation
Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder
Weisler, R. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.6.745 · Cited by 22 · see citing works
Eosinophilic Hepatitis in an Adolescent During Lisdexamfetamine Dimesylate Treatment for ADHD
Hood, B., & Nowicki, M. J. (2010) · PEDIATRICS · doi:10.1542/peds.2009-1835 · Cited by 17 · see citing works
Poison Centers Detect an Unexpectedly Frequent Number of Adverse Drug Reactions to Lisdexamfetamine
Spiller, H. A., Griffith, J. R., Anderson, D. L., Weber, J. A., & Aleguas, A. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l240 · Cited by 17 · see citing works
Alopecia Following Initiation of Lisdexamfetamine in a Pediatric Patient
Brahm, N. C., & Hamilton, D. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08l00753 · Cited by 9 · see citing works

Flagged first, then by citations

Sorted by citations

Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 622 · see citing works
Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options
Hodgkins, P., Shaw, M., Coghill, D., & Hechtman, L. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0286-5 · Cited by 147 · see citing works
Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132 · see citing works
Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review
Quintero, J., Gutiérrez-Casares, J. R., & Álamo, C. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00392-2 · Cited by 70 · see citing works
“All the subsequent analysis was carried out taking into account the active compound, since the parental prodrug is biologically inactive [154].”
Background
Nonmedical Use and Diversion of ADHD Stimulants Among U.S. Adults Ages 18-49
Cassidy, T. A., Varughese, S., Russo, L., Budman, S. H., Eaton, T. A., & Butler, S. F. (2012) · Journal of Attention Disorders · doi:10.1177/1087054712468486 · Cited by 68 · see citing works
Current approaches in tamper-resistant and abuse-deterrent formulations
Mastropietro, D. J., & Omidian, H. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.680468 · Cited by 54 · see citing works
Abuse-deterrent formulations: Part 2: commercial products and proprietary technologies
Mastropietro, D. J., & Omidian, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.970175 · Cited by 39 · see citing works
Child and Caregiver Issues In the Treatment of Attention Deficit–Hyperactivity Disorder: Education, Adherence and Treatment Choice
Ferrín, M., & Taylor, E. A. (2011) · Future Neurology · doi:10.2217/fnl.11.5 · Cited by 39 · see citing works
Methods to Develop an in silico Clinical Trial: Computational Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate
Gutiérrez-Casares, J. R., Quintero, J., Jorba, G., Junet, V., Martínez, V., Pozo-Rubio, T., Oliva, B., Daura, X., Mas, J. M., & Montoto, C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.741170 · Cited by 22 · see citing works
Unraveling Attention-Deficit/Hyperactivity Disorder Etiology: Current Challenges and Future Directions in Treatment
Poddar, A., Gaddam, S., Sonnaila, S., Bhavaraju, V. S. M., & Agrawal, S. (2025) · NeuroSci · doi:10.3390/neurosci6020041 · Cited by 12 · see citing works
In silico clinical trial evaluating lisdexamfetamine’s and methylphenidate’s mechanism of action computational models in an attention-deficit/hyperactivity disorder virtual patients’ population
Gutiérrez-Casares, J. R., Quintero, J., Segú-Vergés, C., Monterde, P. R., Pozo-Rubio, T., Coma, M., & Montoto, C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.939650 · Cited by 5 · see citing works
In silico evaluation of the role of lisdexamfetamine on attention-deficit/hyperactivity disorder common psychiatric comorbidities: mechanistic insights on binge eating disorder and depression
Gutiérrez-Casares, J. R., Segú-Vergés, C., Chueca, J. S., Pozo-Rubio, T., Coma, M., Montoto, C., & Quintero, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1118253 · Cited by 3 · see citing works
Clinical Utility of Lisdexamfetamine for the Management of Attention-Deficit Hyperactivity Disorder
Nguyen, M. L., Shapiro, M. A., & Tharani, S. (2012) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s8706 · Cited by 1 · see citing works
Can exposure to lisdexamfetamine dimesylate from juvenile period to peripubertal compromise male reproductive parameters in adult rats?
Stein, J., Jorge, B. C., Nagaoka, L. T., Reis, A. C. C., Manoel, B. D. M., Godoi, A. R., Fioravante, V. C., Martinez, F. E., Pinheiro, P. F. F., Pupo, A. S., et al. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116867 · Cited by 1 · see citing works

An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder
Wigal, S. B., Raja, P., & Shukla, A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.754013 · Cited by 9 · see citing works
Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents
Mattos, P. (2014) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000007 · Cited by 7 · see citing works
Clinical Utility of Lisdexamfetamine for the Management of Attention-Deficit Hyperactivity Disorder
Nguyen, M. L., Shapiro, M. A., & Tharani, S. (2012) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s8706 · Cited by 1 · see citing works
Update on optimal use of lisdexamfetamine in the treatment of ADHD
Madaan, V., Kolli, V., Bestha, D., & Shah, M. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s34092 · Cited by 19 · see citing works
Untitled work
(2014) · PubMed · Cited by 9 · see citing works

Authors: Dew, R. E., & Kollins, S. H.
Affiliations: Duke University (US)
ORCID: Dew, Rachel E
Kollins, Scott H
Venue: Expert Opinion on Pharmacotherapy
Publisher: Informa Healthcare
Published: 2010-10-28
Volume: 11
Issue: 17
Pages: 2907-2913
ISSN: 1465-6566 (ISSN-L)
1744-7666
DOI: 10.1517/14656566.2010.531009
OpenAlex: W2007288100
Cited by: 14
References: 38
Citations by year: 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 4
FWCI: 1.31
Type: journal article
Language: en
Open access: closed
Locations: Expert Opinion on Pharmacotherapy (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords: lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, stimulant medication, ADHD medication, drug efficacy, drug safety, substance use risk
MeSH terms: Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Dextroamphetamine, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks